Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
Healthcare
$26.75 +0.27%
+$0.09 today
- Market cap
- $1.93B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
52W Low $19.07High $56.05
Volume 1.05M
Average 1.18M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$241.10M
FY 2025 · Annual
Investing Cash Flow
$194.29M
FY 2025 · Annual
Financing Cash Flow
$308.90M
FY 2025 · Annual
-49.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| Deferred Income Tax | (1.8M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.01M | 8.89M | 11.49M | 20.8M | 37.93M |
| Change in Working Capital | 3.51M | 6.75M | (5.87M) | 2.66M | 22.99M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 475K | 10.61M | (873K) | (3.45M) | 13.91M |
| Other Working Capital | 3.04M | (3.86M) | (5M) | 6.11M | 9.08M |
| Other Non-Cash Items | 4M | 6.67M | (1.84M) | (6.1M) | (2.88M) |
| Operating Cash Flow | (23.71M) | (67.6M) | (92.18M) | (134.68M) | (241.1M) |
| Capital Expenditures | 0 | (62K) | (63K) | (972K) | (630K) |
| Acquisitions (Net) | 796K | 70.49K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (148.49M) | (224.93M) | (711.99M) | (310.45M) |
| Sales of Investments | 0 | 78M | 185.56M | 278.96M | 506.16M |
| Other Investing Activities | (5M) | (70.49K) | 0 | 8.97M | (800K) |
| Investing Cash Flow | (4.2M) | (70.55M) | (39.43M) | (425.03M) | 194.29M |
| Debt Repayment | 4.92M | 19.82M | 24.74M | 0 | 23.34M |
| Common Stock Issued | 51.18M | 86.13M | 115M | 632.54M | 307.48M |
| Common Stock Repurchased | 0 | 0 | 0 | (13K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.22M) | (4.01M) | (6.2M) | (25.85M) | (21.92M) |
| Financing Cash Flow | 53.88M | 101.93M | 133.54M | 606.67M | 308.9M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.97M | (36.22M) | 1.93M | 46.97M | 262.08M |
| Free Cash Flow | (23.71M) | (67.66M) | (92.24M) | (135.65M) | (241.73M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$299.6M
+ D&A$468.0K
+ Stock-Based Comp$37.9M
+ Deferred Tax$0
+ Working Capital$23.0M
- Other Non-Cash-$2.9M
= Operating Cash Flow-$241.1M
- Capex-$630.0K
= Free Cash Flow-$241.7M
Analysis
FY2025 free cash flow is -$241.7M. FCF conversion is 80.7% of net income. Operating cash flow was -$241.1M, with capex of -$630.0K. The largest bridge item is Stock-Based Comp at $37.9M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 8-K | Current report | Sep 15, 2026 |
Does VERA generate free cash flow?
Vera Therapeutics, Inc. (VERA) generated -$241.73M of free cash flow in fiscal 2025.
How much operating cash flow does VERA produce?
Operating cash flow was -$241.10M, before capital expenditures of $630,000.00.
Continue the stock analysis
Jump to another research area for this company.